What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Sell
23
CHEOY Quote, Financials, Valuation and Earnings
Last price:
$87.81
Seasonality move
:
5.13%
Day range:
$87.22 - $87.85
52-week range:
$74.76 - $105.60
Dividend yield:
1.58%
P/E ratio:
45.57x
P/S ratio:
7.53x
P/B ratio:
11.45x
Volume:
16.1K
Avg. volume:
16.1K
1-year change:
-4.67%
Market cap:
$11.5B
Revenue:
$1.5B
EPS (TTM):
$1.93
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CHEOY
Cochlear Ltd.
|
-- | -- | -- | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | $12.00 |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | $9.50 |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -- | -- | $19.01 |
|
MESO
Mesoblast Ltd.
|
$20.3M | -- | -100% | -- | $35.00 |
|
PPCB
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CHEOY
Cochlear Ltd.
|
$87.58 | -- | $11.5B | 45.57x | $0.70 | 1.58% | 7.53x |
|
ATHE
Alterity Therapeutics Ltd.
|
$3.29 | $12.00 | $59.6M | -- | $0.00 | 0% | 3.58x |
|
IMMP
Immutep Ltd.
|
$2.58 | $9.50 | $375.5M | -- | $0.00 | 0% | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
$10.43 | $19.01 | $17.4M | -- | $0.00 | 0% | 471.27x |
|
MESO
Mesoblast Ltd.
|
$18.07 | $35.00 | $2.3B | -- | $0.00 | 0% | 126.82x |
|
PPCB
|
$11.98 | -- | $158.1K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CHEOY
Cochlear Ltd.
|
11.66% | 0.901 | -- | 1.41x |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -1.575 | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | 0.640 | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-6.76% | 5.445 | 5.57% | 0.07x |
|
MESO
Mesoblast Ltd.
|
-- | 0.345 | -- | -- |
|
PPCB
|
-- | 4.794 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CHEOY
Cochlear Ltd.
|
-- | -- | 18.67% | 20.19% | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
MESO
Mesoblast Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PPCB
|
-- | -$290.8K | -- | -- | -- | -$235.5K |
Cochlear Ltd. vs. Competitors
-
Which has Higher Returns CHEOY or ATHE?
Alterity Therapeutics Ltd. has a net margin of -- compared to Cochlear Ltd.'s net margin of --. Cochlear Ltd.'s return on equity of 20.19% beat Alterity Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CHEOYCochlear Ltd.-- -- $1.3B ATHEAlterity Therapeutics Ltd.-- -- -- -
What do Analysts Say About CHEOY or ATHE?
Cochlear Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Alterity Therapeutics Ltd. has an analysts' consensus of $12.00 which suggests that it could grow by 264.74%. Given that Alterity Therapeutics Ltd. has higher upside potential than Cochlear Ltd., analysts believe Alterity Therapeutics Ltd. is more attractive than Cochlear Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CHEOYCochlear Ltd.0 0 0 ATHEAlterity Therapeutics Ltd.0 0 0 -
Is CHEOY or ATHE More Risky?
Cochlear Ltd. has a beta of 0.991, which suggesting that the stock is 0.868% less volatile than S&P 500. In comparison Alterity Therapeutics Ltd. has a beta of 0.023, suggesting its less volatile than the S&P 500 by 97.656%.
-
Which is a Better Dividend Stock CHEOY or ATHE?
Cochlear Ltd. has a quarterly dividend of $0.70 per share corresponding to a yield of 1.58%. Alterity Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cochlear Ltd. pays 63.9% of its earnings as a dividend. Alterity Therapeutics Ltd. pays out -- of its earnings as a dividend. Cochlear Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHEOY or ATHE?
Cochlear Ltd. quarterly revenues are --, which are smaller than Alterity Therapeutics Ltd. quarterly revenues of --. Cochlear Ltd.'s net income of -- is lower than Alterity Therapeutics Ltd.'s net income of --. Notably, Cochlear Ltd.'s price-to-earnings ratio is 45.57x while Alterity Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cochlear Ltd. is 7.53x versus 3.58x for Alterity Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHEOYCochlear Ltd.7.53x 45.57x -- -- ATHEAlterity Therapeutics Ltd.3.58x -- -- --
-
Which has Higher Returns CHEOY or IMMP?
Immutep Ltd. has a net margin of -- compared to Cochlear Ltd.'s net margin of --. Cochlear Ltd.'s return on equity of 20.19% beat Immutep Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CHEOYCochlear Ltd.-- -- $1.3B IMMPImmutep Ltd.-- -- -- -
What do Analysts Say About CHEOY or IMMP?
Cochlear Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Immutep Ltd. has an analysts' consensus of $9.50 which suggests that it could grow by 268.22%. Given that Immutep Ltd. has higher upside potential than Cochlear Ltd., analysts believe Immutep Ltd. is more attractive than Cochlear Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CHEOYCochlear Ltd.0 0 0 IMMPImmutep Ltd.1 0 0 -
Is CHEOY or IMMP More Risky?
Cochlear Ltd. has a beta of 0.991, which suggesting that the stock is 0.868% less volatile than S&P 500. In comparison Immutep Ltd. has a beta of 1.925, suggesting its more volatile than the S&P 500 by 92.469%.
-
Which is a Better Dividend Stock CHEOY or IMMP?
Cochlear Ltd. has a quarterly dividend of $0.70 per share corresponding to a yield of 1.58%. Immutep Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cochlear Ltd. pays 63.9% of its earnings as a dividend. Immutep Ltd. pays out -- of its earnings as a dividend. Cochlear Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHEOY or IMMP?
Cochlear Ltd. quarterly revenues are --, which are smaller than Immutep Ltd. quarterly revenues of --. Cochlear Ltd.'s net income of -- is lower than Immutep Ltd.'s net income of --. Notably, Cochlear Ltd.'s price-to-earnings ratio is 45.57x while Immutep Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cochlear Ltd. is 7.53x versus -- for Immutep Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHEOYCochlear Ltd.7.53x 45.57x -- -- IMMPImmutep Ltd.-- -- -- --
-
Which has Higher Returns CHEOY or KZIA?
Kazia Therapeutics Ltd. has a net margin of -- compared to Cochlear Ltd.'s net margin of --. Cochlear Ltd.'s return on equity of 20.19% beat Kazia Therapeutics Ltd.'s return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital CHEOYCochlear Ltd.-- -- $1.3B KZIAKazia Therapeutics Ltd.-- -- -$6.3M -
What do Analysts Say About CHEOY or KZIA?
Cochlear Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kazia Therapeutics Ltd. has an analysts' consensus of $19.01 which suggests that it could grow by 82.25%. Given that Kazia Therapeutics Ltd. has higher upside potential than Cochlear Ltd., analysts believe Kazia Therapeutics Ltd. is more attractive than Cochlear Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CHEOYCochlear Ltd.0 0 0 KZIAKazia Therapeutics Ltd.1 0 0 -
Is CHEOY or KZIA More Risky?
Cochlear Ltd. has a beta of 0.991, which suggesting that the stock is 0.868% less volatile than S&P 500. In comparison Kazia Therapeutics Ltd. has a beta of 1.672, suggesting its more volatile than the S&P 500 by 67.185%.
-
Which is a Better Dividend Stock CHEOY or KZIA?
Cochlear Ltd. has a quarterly dividend of $0.70 per share corresponding to a yield of 1.58%. Kazia Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cochlear Ltd. pays 63.9% of its earnings as a dividend. Kazia Therapeutics Ltd. pays out -- of its earnings as a dividend. Cochlear Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHEOY or KZIA?
Cochlear Ltd. quarterly revenues are --, which are smaller than Kazia Therapeutics Ltd. quarterly revenues of --. Cochlear Ltd.'s net income of -- is lower than Kazia Therapeutics Ltd.'s net income of --. Notably, Cochlear Ltd.'s price-to-earnings ratio is 45.57x while Kazia Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cochlear Ltd. is 7.53x versus 471.27x for Kazia Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHEOYCochlear Ltd.7.53x 45.57x -- -- KZIAKazia Therapeutics Ltd.471.27x -- -- --
-
Which has Higher Returns CHEOY or MESO?
Mesoblast Ltd. has a net margin of -- compared to Cochlear Ltd.'s net margin of --. Cochlear Ltd.'s return on equity of 20.19% beat Mesoblast Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CHEOYCochlear Ltd.-- -- $1.3B MESOMesoblast Ltd.-- -- -- -
What do Analysts Say About CHEOY or MESO?
Cochlear Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Mesoblast Ltd. has an analysts' consensus of $35.00 which suggests that it could grow by 93.69%. Given that Mesoblast Ltd. has higher upside potential than Cochlear Ltd., analysts believe Mesoblast Ltd. is more attractive than Cochlear Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CHEOYCochlear Ltd.0 0 0 MESOMesoblast Ltd.1 0 0 -
Is CHEOY or MESO More Risky?
Cochlear Ltd. has a beta of 0.991, which suggesting that the stock is 0.868% less volatile than S&P 500. In comparison Mesoblast Ltd. has a beta of 2.025, suggesting its more volatile than the S&P 500 by 102.508%.
-
Which is a Better Dividend Stock CHEOY or MESO?
Cochlear Ltd. has a quarterly dividend of $0.70 per share corresponding to a yield of 1.58%. Mesoblast Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cochlear Ltd. pays 63.9% of its earnings as a dividend. Mesoblast Ltd. pays out -- of its earnings as a dividend. Cochlear Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHEOY or MESO?
Cochlear Ltd. quarterly revenues are --, which are smaller than Mesoblast Ltd. quarterly revenues of --. Cochlear Ltd.'s net income of -- is lower than Mesoblast Ltd.'s net income of --. Notably, Cochlear Ltd.'s price-to-earnings ratio is 45.57x while Mesoblast Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cochlear Ltd. is 7.53x versus 126.82x for Mesoblast Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHEOYCochlear Ltd.7.53x 45.57x -- -- MESOMesoblast Ltd.126.82x -- -- --
-
Which has Higher Returns CHEOY or PPCB?
has a net margin of -- compared to Cochlear Ltd.'s net margin of --. Cochlear Ltd.'s return on equity of 20.19% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CHEOYCochlear Ltd.-- -- $1.3B PPCB-- -$0.00 -- -
What do Analysts Say About CHEOY or PPCB?
Cochlear Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Cochlear Ltd. has higher upside potential than , analysts believe Cochlear Ltd. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings CHEOYCochlear Ltd.0 0 0 PPCB0 0 0 -
Is CHEOY or PPCB More Risky?
Cochlear Ltd. has a beta of 0.991, which suggesting that the stock is 0.868% less volatile than S&P 500. In comparison has a beta of 1.881, suggesting its more volatile than the S&P 500 by 88.104%.
-
Which is a Better Dividend Stock CHEOY or PPCB?
Cochlear Ltd. has a quarterly dividend of $0.70 per share corresponding to a yield of 1.58%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cochlear Ltd. pays 63.9% of its earnings as a dividend. pays out -- of its earnings as a dividend. Cochlear Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHEOY or PPCB?
Cochlear Ltd. quarterly revenues are --, which are smaller than quarterly revenues of --. Cochlear Ltd.'s net income of -- is lower than 's net income of -$354.3K. Notably, Cochlear Ltd.'s price-to-earnings ratio is 45.57x while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cochlear Ltd. is 7.53x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHEOYCochlear Ltd.7.53x 45.57x -- -- PPCB-- -- -- -$354.3K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 15
Frequency Electronics, Inc. [FEIM] is down 4.71% over the past day.
Buy
57
MOD alert for Dec 15
Modine Manufacturing Co. [MOD] is up 2.69% over the past day.
Sell
42
OKLO alert for Dec 15
Oklo, Inc. [OKLO] is down 4.04% over the past day.
